A Phase 1/2 Trial of Multiple Oral Doses of OPC‑167832 for Uncomplicated Pulmonary Tuberculosis

Sponsor ID
323-201-00003
Clinicaltrials.gov ID
NCT03678688
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Study Complete
Sponsor ID
323-201-00003
Trial Details
Subscribe for updates
Age
18 - 64 Years
Therapeutic Area
  • Tuberculosis
    • Sex
    Female & Male
    Trial Dates
    Oct 2018 - Feb 2022
    Healthy Volunteers
    No
    • Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements of the trial.
    • Male or female participants between 18 and 64 years of age (inclusive) at the screening visit.
    • Body mass index ≥ 16.0 and ≤ 32.0 kilograms per meters squared (kg/m\^2) (inclusive) at the screening visit.
    • Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB.
    • Microscopy performed on a sputum smear at screening indicates presence of acid-fast bacilli (at least 1+).
    • Able to produce an adequate volume of sputum (approximately 10 millilitres (mL) or more estimated overnight production).
    • Female participants of childbearing potential must agree to use 2 different approved methods of birth control or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment (investigational medicinal product (IMP) or RHEZ).
    • Male participants must agree to use 2 different approved methods of birth control or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment (IMP or RHEZ).
    • Participants are known or suspected of having resistance to rifampicin, isoniazid, ethambutol, or pyrazinamide using any combination of Xpert Mycobacterium tuberculosis/Rifampin (MTB/RIF), line probe assay, culture, and/or epidemiologic history at screening.
    • Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
    • Evidence of clinically significant metabolic (including ongoing or current hypokalemia), gastrointestinal, neurological, psychiatric, endocrine or liver (e.g., hepatitis B and C) disease; malignancy; or other abnormalities (other than the indication being studied).
    • History of or current clinically relevant cardiovascular disorder such as heart failure, coronary heart disease, hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
    • Known bleeding disorders or family history of bleeding disorders.
    • Any diseases or conditions in which the use of delamanid, rifampicin, isoniazid, pyrazinamide, ethambutol, or Bedaquiline is contraindicated.
    • Any prior treatment for M. tuberculosis within the past 3 years.
    • Any treatment with a drug active against M. tuberculosis (e.g., quinolones) within the 3 months prior to screening.
    • Clinical evidence of severe extrapulmonary TB (e.g., miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
    • Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB). In particular any underlying condition that could interfere with the assessment of x-ray images, sputum collection, or interpretation of sputum findings, or otherwise compromise the subject's participation in the trial.
    • Any renal impairment characterized by serum creatinine clearance of \<60 millilitres per minute (mL/min), or hepatic impairment characterized by alanine transaminase, aspartate transaminase, or total bilirubin \>1.5 x upper limit of normal (ULN) of the clinical laboratory reference range at screening.
    • For Stage 1, participants who are human immunodeficiency virus (HIV) positive are excluded. For Stage 2, participants with HIV co-infection who are on antiretroviral drugs during screening or with CD4 cell count \<500/ millimeters cubed (mm\^3) are excluded.
    • Changes in the electrocardiogram (ECG) such as QTcF \>450 milliseconds (msec), atrioventricular block II or III, bi-fasicular block, at screening or current history of clinically significant ventricular arrhythmias. Other ECG changes if considered clinically significant by the investigator.
    • Participants receiving any of the prohibited medications within the specified periods or who would be likely to require prohibited concomitant therapy during the trial.
    • Female participants who are breast-feeding or who have a positive pregnancy test result prior to receiving the first dose of IMP or RHEZ on Day 1.
    • History of significant drug and/or alcohol abuse within 2 years prior to screening.
    • History of or current hepatitis or carriers of HBsAg and/or anti-HCV.
    • Positive urine or blood alcohol test and/or urine drug screen for substance abuse at screening (not including cannabinoids).
    • History of having taken an investigational drug within 30 days preceding trial entry (ie, prior to screening).
    • A history of difficulty in donating blood.
    • Donation of blood or plasma within 30 days prior to dosing.
    • Consumption of alcohol and/or grapefruit, grapefruit juice, Seville oranges, or Seville orange juice and related products within 72 hours prior to the first dose of IMP or RHEZ on Day 1.
    • History of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial.
    • Any known prior exposure to OPC-167832, delamanid or Bedaquiline.
    • Participants with significant medical comorbidities that in the opinion of the investigator, should not participate in the trial.

    Study Summary

    This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).

    Additional Study Details

    Phase
    Phase 1/Phase 2
    Study Drug
    Drug: 10 mg OPC-167832
    Type
    Interventional
    Masking
    None (Open Label)
    Estimated Enrollment
    122
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • * Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements of the trial.
    • * Male or female participants between 18 and 64 years of age (inclusive) at the screening visit.

    Exclusion Criteria

    • * Participants are known or suspected of having resistance to rifampicin, isoniazid, ethambutol, or pyrazinamide using any combination of Xpert Mycobacterium tuberculosis/Rifampin (MTB/RIF), line probe assay, culture, and/or epidemiologic history at screening.
    • * Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements of the trial.
    • Male or female participants between 18 and 64 years of age (inclusive) at the screening visit.
    • Body mass index ≥ 16.0 and ≤ 32.0 kilograms per meters squared (kg/m\^2) (inclusive) at the screening visit.
    • Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB.
    • Microscopy performed on a sputum smear at screening indicates presence of acid-fast bacilli (at least 1+).
    • Able to produce an adequate volume of sputum (approximately 10 millilitres (mL) or more estimated overnight production).
    • Female participants of childbearing potential must agree to use 2 different approved methods of birth control or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment (investigational medicinal product (IMP) or RHEZ).
    • Male participants must agree to use 2 different approved methods of birth control or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment (IMP or RHEZ).
    Exclusion Criteria:
    • Participants are known or suspected of having resistance to rifampicin, isoniazid, ethambutol, or pyrazinamide using any combination of Xpert Mycobacterium tuberculosis/Rifampin (MTB/RIF), line probe assay, culture, and/or epidemiologic history at screening.
    • Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
    • Evidence of clinically significant metabolic (including ongoing or current hypokalemia), gastrointestinal, neurological, psychiatric, endocrine or liver (e.g., hepatitis B and C) disease; malignancy; or other abnormalities (other than the indication being studied).
    • History of or current clinically relevant cardiovascular disorder such as heart failure, coronary heart disease, hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
    • Known bleeding disorders or family history of bleeding disorders.
    • Any diseases or conditions in which the use of delamanid, rifampicin, isoniazid, pyrazinamide, ethambutol, or Bedaquiline is contraindicated.
    • Any prior treatment for M. tuberculosis within the past 3 years.
    • Any treatment with a drug active against M. tuberculosis (e.g., quinolones) within the 3 months prior to screening.
    • Clinical evidence of severe extrapulmonary TB (e.g., miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
    • Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB). In particular any underlying condition that could interfere with the assessment of x-ray images, sputum collection, or interpretation of sputum findings, or otherwise compromise the subject's participation in the trial.
    • Any renal impairment characterized by serum creatinine clearance of \<60 millilitres per minute (mL/min), or hepatic impairment characterized by alanine transaminase, aspartate transaminase, or total bilirubin \>1.5 x upper limit of normal (ULN) of the clinical laboratory reference range at screening.
    • For Stage 1, participants who are human immunodeficiency virus (HIV) positive are excluded. For Stage 2, participants with HIV co-infection who are on antiretroviral drugs during screening or with CD4 cell count \<500/ millimeters cubed (mm\^3) are excluded.
    • Changes in the electrocardiogram (ECG) such as QTcF \>450 milliseconds (msec), atrioventricular block II or III, bi-fasicular block, at screening or current history of clinically significant ventricular arrhythmias. Other ECG changes if considered clinically significant by the investigator.
    • Participants receiving any of the prohibited medications within the specified periods or who would be likely to require prohibited concomitant therapy during the trial.
    • Female participants who are breast-feeding or who have a positive pregnancy test result prior to receiving the first dose of IMP or RHEZ on Day 1.
    • History of significant drug and/or alcohol abuse within 2 years prior to screening.
    • History of or current hepatitis or carriers of HBsAg and/or anti-HCV.
    • Positive urine or blood alcohol test and/or urine drug screen for substance abuse at screening (not including cannabinoids).
    • History of having taken an investigational drug within 30 days preceding trial entry (ie, prior to screening).
    • A history of difficulty in donating blood.
    • Donation of blood or plasma within 30 days prior to dosing.
    • Consumption of alcohol and/or grapefruit, grapefruit juice, Seville oranges, or Seville orange juice and related products within 72 hours prior to the first dose of IMP or RHEZ on Day 1.
    • History of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial.
    • Any known prior exposure to OPC-167832, delamanid or Bedaquiline.
    • Participants with significant medical comorbidities that in the opinion of the investigator, should not participate in the trial.

    Study Documents

    Study Protocol
    Available Languages: English
    DOWNLOAD DOCUMENT(S)
    Statistical Analysis Plan
    Available Languages: English
    DOWNLOAD DOCUMENT(S)

    Locations

    Location
    Status
    Location
    University of Cape Town (Pty) Ltd.
    Cape Town, Mowbray, South Africa, 7700
    Status
    N/A
    Location
    Satellite Site: Task at Brooklyn Chest Hospital
    Cape Town, South Africa, 7405
    Status
    N/A
    Location
    TASK Clinical Research Centre
    Cape Town, South Africa, 7530
    Status
    N/A

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974